Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary
KEYWORDS: iiia, iib, iib iiia, patients, pci, inhibitors, iiia inhibitors, acs, use, management, treatment, risk, coronary, cost, inhibitor

hours, up to a maximum duration of treatment of 108 hours. 3.3.3 As with the other GP IIb/IIIa inhibitors, the side effects of tirofiban (including bleeding and thrombocytopenia) are related to its pharmacological effects. For full details of side effects and contraindications, see the summary of product characteristics. 3.3.4 The cost of tirofiban is £146.11 (net) for a 12.5-mg vial (BNF 43rd edition). For a 70-kg person, the cost per course ranges from £292 to £584, depending on the duration of treatment (costs rounded to full vials). 4 Evidence and interpretation The appraisal committee considered evidence from a number of sources. Each indication was considered separately. 4.1 Clinical effectiveness 4.1.1 GP IIb/IIIa inhibitors for the medical management of ACSs 4.1.1.1 The assessment group found 1 new study (GUSTO IV), in addition to 4 studies from the previous appraisal that are relevant to this review. All were classified as randomised controlled trials (RCTs) that included patients with unstable angina or NSTEMI, but the definitions of the participants varied between trials. Two studies looked at eptifibatide, 2 at tirofiban and 1 at abciximab; all these studies compared treatment with placebo or no treatment. On the whole, the studies were well conducted. Outcome
